Chicago’s most valuable tech startup made multiple moves this week as it looks to expand its genomic-sequencing technology.
Tempus announced Wednesday that it has acquired AKESOgen, an Atlanta-based genomics lab and data company that provides sequencing, biomarker profiling and other analysis to clients in biotech, pharmaceutical, government and other industries. Terms of the deal weren’t disclosed, but the company said the move will help it expand into disease areas outside of cancer and operate lab space beyond its Chicago headquarters.
Tempus, a cancer-fighting startup from Groupon founder Eric Lefkofsky, uses machine learning and genomic sequencing to better understand a patient’s tumor and tailors treatment plans best suited to combat it. The startup said earlier this year it planned to bring its genomic-sequencing tech to areas beyond cancer, including diabetes and depression.
“AKESOgen’s breadth of capabilities strategically complement our own, and we look forward to bringing the power of data and artificial intelligence to healthcare and advancing the field of precision medicine together,” Lefkofsky said in a statement.